MarketPulse

regulatory prospects

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Atara Biotherapeutics Hit With Securities Lawsuit Over Manufacturing, Study Claims

Rosen Law Firm urges $ATRA investors to meet May 22, 2026 deadline in securities lawsuit alleging false statements about manufacturing and clinical trial deficiencies.
ATRAsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Atara Biotherapeutics Faces Securities Fraud Suit Over Concealed FDA Obstacles

Class action lawsuit alleges $ATRA misrepresented manufacturing issues and clinical trial deficiencies for tabelecleucel, obscuring FDA approval challenges between May 2024 and January 2026.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Atara Biotherapeutics Hit With Class Action Over Misleading Manufacturing Claims

Bronstein, Gewirtz & Grossman files class action against $ATAR, alleging executives misled investors about manufacturing issues and FDA approval prospects for tabelecleucel.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

ATRA Faces Securities Fraud Lawsuit Over Misleading FDA Prospects and Manufacturing Claims

Class action lawsuit filed against Atara Biotherapeutics alleging false statements about manufacturing issues and regulatory prospects for tabelecleucel.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

Inovio Faces Securities Fraud Lawsuit Over Misleading Statements on Drug Candidate

Class action lawsuit filed against Inovio Pharmaceuticals ($INO) for allegedly making false statements about INO-3107 treatment and manufacturing capabilities, causing significant stock declines.
INOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

Inovio Faces Securities Fraud Lawsuit Over INO-3107 Misstatements

Class action lawsuit filed against $INO for allegedly false statements about INO-3107 treatment and CELLECTRA device. Lead plaintiff deadline is April 7, 2026.
INOsecurities fraudclass action lawsuit